TITLE

White cells count in smokers affected by rheumatic diseases

AUTHOR(S)
Bartolone, Sebastiano; Calzavara, Emilse; Russo, Giuseppina; Carnì, Antonio; Mannucci, Carmen; Pieratti, Antonella; Caputi, Achille; Calapai, Gioacchino
PUB. DATE
January 2012
SOURCE
Rheumatology International;Jan2012, Vol. 32 Issue 1, p109
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Evidence shows that tobacco smoking interacts with development of rheumatic diseases. Increase in white cells count (leukocytosis) is frequently present, and in smokers, it is considered a biomarker of cardiovascular risk. Aim of the study is to evaluate this biomarker in smokers with rheumatic diagnosis. We carried out an observational study on 115 rheumatic outpatients (26 men and 89 women) divided into two groups according to their smoking habit: one composed of 56 smokers, the other of 59 not smokers. Diagnosis and common routinary clinical parameters were collected. In the total sample, smokers were 48.69%. Most common diagnosis was osteoarthritis (OA) (40.87% of the total); smokers in OA women were 36.11%, smokers in OA men were 54.55%. Second most common diagnosis was rheumatoid arthritis (RA) (23.48% of the total); smokers in RA women were 40.91%; smokers in RA men were 80%. OA smokers showed a significant increase ( P < 0.05) in white cells count when compared with OA not smokers. Between RA smokers and not smokers, any clinical difference was found. RA subjects following regular pharmacological treatment in the last 2 months were 84.61%. OA patients treated with drugs in the last 2 months were only 22.2%. Results seem to confirm that smoking habit may influence the development as well as gender distribution of rheumatic diseases. They show also that in absence of pharmacological treatment in smokers affected by OA leukocytosis (biomarker of cardiovascular risk) is observed.
ACCESSION #
70162175

 

Related Articles

  • Monoarticular septic arthritis in a patient with juvenile rheumatoid arthritis under etanercept treatment. Lin, Kai-Cheng; Liang, Chi-Di; Yang, Kuender; Yu, Hong-Ren; Kuo, Ho-Chang // Rheumatology International;May2012, Vol. 32 Issue 5, p1383 

    A 7-year-old girl with polyarticular type juvenile rheumatoid arthritis (JRA) presented with acute onset of right hip pain with limited range of motion and fever within the past two days. She had received etanercept for more than one year. Percutaneous arthrocentesis was performed and showed a...

  • Adalimumab for Rheumatoid Arthritis? Ebell, Mark; Kripke, Clarissa // American Family Physician;2/1/2006, Vol. 73 Issue 3, p435 

    Answers a question on the safety and effectiveness of adalimumab (Humira) for rheumatoid arthritis. Required dosage of adalimumab; Effectiveness of the combination of adalimumab with methotrexate; Indications for adalimumab.

  • The patient-based outcome of upper-extremity surgeries using the DASH questionnaire and the effect of disease activity of the patients with rheumatoid arthritis. Ishikawa, Hajime; Murasawa, Akira; Nakazono, Kiyoshi; Abe, Asami; Otani, Hiroshi; Netsu, Tahahiro; Sakai, Takehito; Sato, Hiroe // Clinical Rheumatology;Aug2008, Vol. 27 Issue 8, p967 

    The Disabilities of the Arm, Shoulder and Hand (DASH) is a standardized patient-based outcome measure, which assesses integrated upper-extremity disorders. The objectives of this study were to investigate subjective outcome after upper-extremity surgeries for the patients with rheumatoid...

  • Need to Avoid Handshakes. Kellery, Kay // Arthritis Today;Mar/Apr2008, Vol. 22 Issue 2, p12 

    The article seeks advice for dealing with the hand-shaking experienced by her daughter who was diagnosed with rheumatoid arthritis. The shaking of the hands can be extremely painful and the patient does not want to appear rude or call attention to her condition.

  • The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients. Chung, Cecilia P.; Russell, Anthony S.; Segami, Maria I.; Ugarte, César A. // Rheumatology International;Mar2005, Vol. 25 Issue 2, p114 

    Objective: The aim of this study was to determine the difference between bone mineral density (BMD) of rheumatoid arthritis (RA) patients on low-dose prednisone and matched RA patients without prior systemic corticosteroid therapy. Methods: Ninety patients attending our clinics and receiving 10...

  • New developments in ochronosis: review of the literature. Keller, Julie M.; Macaulay, William; Nercessian, Ohannes A.; Jaffe, Israeli A. // Rheumatology International;Mar2005, Vol. 25 Issue 2, p81 

    Ochronosis commonly affects all connective tissue. Recognition of changes secondary to the deposition of ochronotic pigments has increased with advances in diagnostic technology, allowing both improved imaging and early biochemical and genetics-based diagnosis of alkaptonuria, the cause of...

  • Adalimumab provides "clinically important" HRQOL gains in RA.  // PharmacoEconomics & Outcomes News;12/3/2005, Issue 492, p13 

    The article presents information on a study conducted on the benefits of adalimumab to patients with severe, reactive rheumatoid arthritis. The results of the study were presented at the 8th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research which...

  • Editorials: Sulphasalazine in rheumatoid arthritis: an old drug revived. Neumann, V. C.; Grindulis, K. A. // Journal of the Royal Society of Medicine;Mar1984, Vol. 77 Issue 3, p169 

    The article discusses the benefits of sulphasalazine in treating rheumatoid arthritis. Sulphasalazine is an old drug which is a compound of sulphapyridine and 5-aminosalicylic acid linked by an azo bond. The benefits of salicylates in rheumatoid arthritis have an excellent effect on the...

  • Fibromyalgic rheumatoid arthritis and disease assessment. Pollard, Louise C.; Kingsley, Gabrielle H.; Choy, Ernest H.; Scott, David L. // Rheumatology;May2010, Vol. 49 Issue 5, p924 

    Objective. We evaluated fibromyalgic RA to determine its clinical impact, identification using core clinical assessments and influence identifying active disease using disease activity scores (DAS-28).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics